초록 ▼

In an emergency medicine patient, accurate measurement of change or lack thereof from non-shock, non-ischemic, non-inflammation, non-tissue injury, non-immune dysfunction conditions is important and is provided, as practical, real-time approaches for accurately characterizing a patient's condition,

In an emergency medicine patient, accurate measurement of change or lack thereof from non-shock, non-ischemic, non-inflammation, non-tissue injury, non-immune dysfunction conditions is important and is provided, as practical, real-time approaches for accurately characterizing a patient's condition, using Raman (3) and/or fluorescence (30) spectroscopy with a high degree of accuracy. Measurement times are on the order of seconds. High-accuracy measurement is achieved with Raman spectroscopy interrogation of tissue. Simultaneous interrogation by NADH fluorescence spectroscopy may he used. Measurements may be non-invasive to minimally invasive. Preclinical (ultra-early) states of shock can be detected (5), severity can be determined, effectiveness of various treatments can be determined.

대표청구항 ▼

We claim: 1. A tissue analysis method, comprising: interrogating a biological tissue with Raman spectroscopy and fluorescence spectroscopy to obtain spectroscopy results; analyzing the obtained spectroscopy results for at least one mediator or marker associated with a shock state. 2. The method

We claim: 1. A tissue analysis method, comprising: interrogating a biological tissue with Raman spectroscopy and fluorescence spectroscopy to obtain spectroscopy results; analyzing the obtained spectroscopy results for at least one mediator or marker associated with a shock state. 2. The method of claim 1, wherein the tissue interrogating is noninvasive. 3. The method of claim 1, wherein the tissue is in vivo and in situ. 4. The method of claim 1, wherein the tissue is removed from a patient before the tissue interrogation. 5. The method of claim 1, including measuring NADH presence and/or accumulation by fluorescence spectroscopy. 6. The method of claim 1, including measuring tissue hemoglobin oxygen saturation by Raman spectroscopy and measuring NADH presence and/or accumulation by fluorescence spectroscopy. 7. The method of claim 1, including determining whether the tissue has insufficient oxygen delivery to meet metabolic demands of the tissue while simultaneously determining whether mitochondrial dysfunction or injury exists. 8. The method of claim 1, including measuring myoglobin oxygenation saturation. 9. The method of claim 1, including determining cytochrome oxidase redox status. 10. The method of claim 1, including determining absolute concentration of hemoglobin in the tissue. 11. The method of claim 1, including determining pH of the tissue. 12. The method of claim 1, including intermittently or continuously interrogating the tissue of a patient. 13. The method of claim 1, including determining tissue viability. 14. The method of claim 1, including diagnosing shock. 15. A tissue analysis method, comprising: interrogating a biological tissue with Raman spectroscopy and fluorescence spectroscopy to obtain spectroscopy results, including: measuring tissue hemoglobin oxygen saturation including amount of oxyhemoglobin and deoxyhemoglobin by Raman spectroscopy; and/or measuring tissue hemoglobin oxygen saturation by Raman spectroscopy and measuring NADH presence and/or accumulation by fluorescence spectroscopy; and/or determining whether the tissue has insufficient oxygen delivery to meet metabolic demands of the tissue while simultaneously determining whether mitochondrial dysfunction or injury exists. 16. The tissue analysis method of claim 15, wherein the obtained spectroscopy results are for at least one mediator or marker associated with a shock state and/or tissue injury. 17. The method of claim 16, wherein the obtained spectroscopy results are for presence and/or proportions for the at least one shock state and/or tissue injury mediator or marker. 18. The method of claim 16 including determining the concentration of at least one mediator or marker. 19. The method of claim 18, including determining absolute concentration. 20. The method of claim 18, including determining relative concentration. 21. The method of claim 16 including determining the presence of at least one mediator or marker. 22. The method of claim 16, wherein the obtained spectroscopy results are selected from the group consisting of at least one mediator associated with a shock state, tissue injury or tissue ischemia, inflammation or immune dysfunction, and at least one marker of tissue perfusion or injury. 23. The method of claim 22, wherein the marker may be within intracellular, interstitial or intravascular space or within exhaled air from a patient. 24. The method of claim 22, wherein the marker is selected from the group consisting of lactate, pyruvate, ATP, Pcr, AMP, ADP, Pi, NAD, NADH, albumin, endotoxin, exotoxin, microbes, cytokines-chemokines, procalcitonin, hormones, myeloperoxidase, elastase, xanthine oxidase, xanthine dehydrogenase, fatty acid binding proteins, catecholamines and vasoactive peptides. 25. The method of claim 22, wherein the marker or mediator is a metabolic or pro or anti-inflammatory marker or mediator. 26. The method of claim 16, including monitoring for appearance of one or more tissue markers specific for a specific disease state. 27. The method of claim 16, including diagnosing tissue injury, tissue inflammation or tissue immune dysfunction. 28. The method of claim 15, including diagnosing and/or following progression or resolution of shock states and/or tissue injury, and/or tissue ischemia. 29. The method of claim 28, wherein the tissue injury includes inflammatory or immune dysfunction. 30. The method of claim 15, including determining absolute concentration of hemoglobin in the tissue. 31. The method of claim 15, including determining pH of the tissue. 32. The method of claim 15, including continuously interrogating the patient for appearance of abnormal tissue markers specific for a suspected disease state. 33. The method of claim 32, wherein the markers are cardiac biomarkers, GI markers, cerebral markers, skin markers, lung markers, blood markers, and/or eye markers. 34. The tissue analysis method of claim 15, including measuring tissue hemoglobin oxygen saturation including amount of oxyhemoglobin and deoxyhemoglobin by Raman spectroscopy. 35. The tissue analysis method of claim 15, including measuring tissue hemoglobin oxygen saturation by Rama spectroscopy and measuring NADH presence and/or accumulation by fluorscence spectroscopy. 36. The tissue analysis method of claim 15, including determining whether the tissue has insufficient oxygen delivery to meet metabolic mends of the tissue while simultaneously determining whether mitochondrial dysfunction or injury exists. 37. A method of diagnosing shock, comprising: (A) for a target molecule population, taking a sample Raman spectroscopy, and/or fluorescence spectroscopy, profile for a patient; (B) comparing the sample spectroscopy profile with a pre-established Raman spectroscopy and/or fluorescence spectroscopy profile for the target molecule population under baseline conditions; and, (C) diagnosing shock based on results of the comparing step. 38. The method of claim 37, wherein the method is non-invasive. 39. The method of claim 37, wherein the target molecule population comprises oxygenated hemoglobin, deoxygenated hemoglobin and/or NADH. 40. The method of claim 37, wherein the profiles are of relative amounts. 41. The method of claim 40, including operating an electromagnetic radiation generator at a range of selectable wavelengths from about 270 mm to about 30,000 nm. 42. The method of claim 37, wherein the profiles are of absolute amounts. 43. The method of claim 37, including taking the profiles by Raman spectroscopy. 44. The method of claim 43, including signal enhancement at a resonant frequency for a target molecule of the target molecule population. 45. The method of claim 37, including monitoring a specific tissue bed in the patient. 46. The method of claim 45, wherein the specific tissue bed is a brain, heart, lung, liver, eye, intestines, stomach, pancreas, kidney, bladder, urethra, skin, nailbed, cervix, uterus, oropharynx, nasopharynx, eosphagus or blood. 47. The method of claim 37, including calculating pH of blood and/or tissue. 48. The method of claim 37, including minimally invasively probing the patient by a fiber optic probe or probe array inserted into a tissue bed. 49. The method of claim 48, wherein the probe or probe array is inserted into a muscle. 50. The method of claim 37, including analysis of interstitial fluid. 51. The method of claim 32, including resonance Raman spectroscopy at 390 to 420 nm wavelength. 52. The method of claim 51, wherein the sample profile is taken from a tissue or a space in a body. 53. The method of claim 51, wherein the sample profile is taken from a tissue or a space out of the body. 54. The method of claim 37, including cellular analysis. 55. The method of claim 37, including placing a probe on or near any mucosal or epithelial covered surface of a body or an organ. 56. The method of claim 37, including simultaneously performing fluorescence spectroscopy probing of NADH while performing Raman spectroscopy. 57. The method of claim 37, wherein spectroscopy is performed for multiple wavelengths. 58. A method of diagnosing shock, tissue ischemia, tissue injury, tissue inflammation, or tissue immune dysfunction, comprising: (A) for a target molecule population, taking a sample Raman spectroscopy, and/or fluorescence spectroscopy, profile for a patient; (B) comparing the sample spectroscopy profile with a pre-established Raman spectroscopy and/or fluorescence spectroscopy profile for the target molecule population under baseline conditions, wherein the profiles are of relative amounts of NAD/NADH; lactate/pyruvate; Pcr-ATP; ATP-ADP; Pcr-Pi; oxidized cytochrome oxidase to reduced cytochrome oxidase, and/or oxyhemoglobin with deoxyhemoglobin. 59. A method of diagnosing shock, tissue ischemia, tissue injury, tissue inflammation, or tissue immune dysfunction, comprising: (A) for a target molecule population, taking a sample Raman spectroscopy, and/or fluorescence spectroscopy, profile for a patient; (B) comparing the sample spectroscopy profile with a pre-established Raman spectroscopy and/or fluorescence spectroscopy profile for the target molecule population under baseline conditions, including detecting exhaled markers or mediators of organ injury. 60. The method of claim 59, wherein exhaled markers or mediators of lung injury are detected. 61. The method of claim 59, wherein a detector is placed at the airway of the patient. 62. The method of claim 59, wherein the exhaled markers indicate organ injury. 63. The method of claim 59, wherein the exhaled markers or mediators are isoprostanes and/or myeloperoxidase. 64. A method of diagnosing abnormalities in vivo and in situ, comprising: (A) for a target molecule population, taking a sample Raman spectroscopy and/or fluorescence spectroscopy profile for a patient; (B) comparing the sample Raman spectroscopy or fluorescence spectroscopy profile with a pre-established Raman spectroscopy or fluorescence spectroscopy profile for the target molecule population under baseline conditions; (C) using differences identified in said comparing step to identify an abnormality associated with a shock state. 65. The method of claim 64, including, while taking the Raman spectroscopy profile, also performing fluorescence spectroscopy measurement on the patient. 66. A computer system comprising: a database of stored baseline Raman spectroscopy and/or fluorescence spectroscopy profiles and a means to store patient Raman spectroscopy and/or fluorescence spectroscopy profiles; including a computing system for comparing patient profiles to baseline profiles with regard to a shock state. 67. A biological material analysis method, comprising: interrogating a biological material with Raman spectroscopy and fluorescence spectroscopy to obtain spectroscopy results; analyzing the obtained spectroscopy results for at least one mediator or marker associated with a shock state. 68. The biological material analysis method of claim 67, wherein the biological material is bodily fluid. 69. The biological material analysis method of claim 67, wherein the biological material is tissue. 70. The method of claim 67, wherein the marker is contained in a biological material selected from the group consisting of urine, saliva, wound exudates, vitreous humor, aqueous humor, tissue exudate, gastric contents, and fecal matter.